Skip to main content

Table 2 Antitumor activity grouped by CD8 status (N=48)

From: Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial

Antitumor activity

All

10-20% (n=35)

> 20% (n=13)

Objective response

39 (81.3, 70.2-92.3)

26 (74.3, 56.7-87.5)

13 (100, 75.3-100)

Best overall response

 Complete response

5 (10.4)

5 (14.3)

0 (0)

 Partial response

34 (70.8)

21 (60.0)

13 (100)

 Stable disease

5 (10.4)

5 (14.3)

0 (0)

 Progressive disease

2 (4.2)

2 (5.7)

0 (0)

 Unknown

2 (4.2)*

2 (5.7)

0 (0)

  1. Data are presented as No. (%, 95% CI) or No. (%)
  2. Responses were assessed in accordance with RECIST version 1.1. Only confirmed responses were included
  3. *Two patients exempted post-baseline efficacy assessments